BRIEF-Cerus announces exercise of additional BARDA contract options for activities related to its planned Phase III trial of the Intercept Red Blood Cell System
* Cerus Corp - Total value of full five-year contract has
also increased to be worth up to $185 million in non-dilutive
No comments:
Post a Comment